BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Citi
Cantor Fitzgerald
Chinese Patent Office
Chubb
Federal Trade Commission
Fish and Richardson
Argus Health
UBS
Covington

Generated: January 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,133,879

« Back to Dashboard

Which drugs does patent 8,133,879 protect, and when does it expire?

Patent 8,133,879 protects LEXISCAN and is included in one NDA.

This patent has twelve patent family members in twelve countries.
Summary for Patent: 8,133,879
Title:Myocardial perfusion imaging methods and compositions
Abstract: The present disclosure provides 2-adenosine N-pyrazole compounds of structural formula shown below that are potent and selective agonists for A.sub.2A adenosine receptor, compositions comprising these compounds, and methods for using these compounds in a variety of applications including myocardial perfusion imaging methods. ##STR00001##
Inventor(s): Belardinelli; Luiz (Palo Alto, CA), Rosner; Mitchell (Mountain View, CA)
Assignee: Gilead Sciences, Inc. (Foster City, CA)
Application Number:12/749,328
Patent Claim Types:
see list of patent claims
Composition; Compound; Delivery;

Drugs Protected by US Patent 8,133,879

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Astellas LEXISCAN regadenoson SOLUTION;INTRAVENOUS 022161-001 Apr 10, 2008 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,133,879

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,289,446 Myocardial perfusion imaging methods and compositions ➤ Subscribe
7,683,037 Myocardial perfusion imaging method ➤ Subscribe
8,183,226 Myocardial perfusion imaging method ➤ Subscribe
8,906,878 Myocardial perfusion imaging methods and compositions ➤ Subscribe
8,470,801 Myocardial perfusion imaging methods and compositions ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,133,879

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Mexico PA05001123 ➤ Subscribe
China 1671399 ➤ Subscribe
Norway 20051059 ➤ Subscribe
European Patent Office 1524984 ➤ Subscribe
Israel 166555 ➤ Subscribe
Japan 2005538190 ➤ Subscribe
New Zealand 537975 ➤ Subscribe
South Korea 20050026546 ➤ Subscribe
Canada 2492855 ➤ Subscribe
Australia 2003259264 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

UBS
Accenture
Express Scripts
McKinsey
AstraZeneca
Johnson and Johnson
McKesson
Queensland Health
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot